

**Amendments to the Claims:**

The following listing of claims will replace all prior versions and listing of claims in the application.

**Listing of Claims:**

1. (Original) Use in preparation of a medicament for treating a mammalian patient suffering from physical trauma, or treating a mammalian patient at risk of suffering such trauma to lessen the severity of and/or accelerate the recovery from such trauma, of immune system-modifying entities, each comprising a body of a size similar to an apoptotic mammalian cell or apoptotic body, and having exposed on its surface phospho-glycerol groups, the entities being capable of modulating the patient's immune system with accompanying beneficial effects including inhibition of pro-inflammatory cytokines and/or promotion of anti-inflammatory cytokines.
2. (Original) Use according to claim 1 wherein the entities are synthetic beads carrying phospho-glycerol groups.
3. (Original) Use according to claim 1 wherein said entities are PG liposomes.
4. (Original) Use according to claim 3 wherein the PG liposomes comprise from 50% to 100% PG by weight.
5. (Currently Amended) Use according to ~~any preceding~~ claim 1 wherein the bodies have a diameter of from 50 nanometers to 500 microns.
6. (Currently Amended) Use according to ~~any preceding~~ claim 1 wherein the unit dose is from about 500 to about  $20 \times 10^9$  entities.
7. (Original) A process of treating a mammalian patient suffering from physical trauma, or treating a mammalian patient at risk of suffering such trauma (by surgical treatment, or by suffering unanticipated accidental injuries, battle injuries or the like) to lessen the severity of and/or accelerate the recovery from such trauma, which comprises administering to the patient an effective immune system modifying amount of immune system-modifying entities, each comprising a body of a size similar to an apoptotic mammalian cell or apoptotic body, and

having exposed on its surface phospho-glycerol groups, the entities being capable of being taken up by cells of the patient's immune system with accompanying beneficial effects including inhibition of pro-inflammatory cytokines and/or promotion of anti-inflammatory cytokines.

8. (Original) The process of claim 7 wherein said entities are phosphatidylglycerol liposomes.

9. (Original) The process of claim 7 wherein the phosphatidylglycerol liposomes have a size from 50 nanometers to 500 microns.

10. (Original) The process according to claim 7 wherein the entities are synthetic beads carrying phospho-glycerol groups.

11. (Original) The process according to claim 8 wherein the PG liposomes comprise from 50% to 100% PG by weight.

12. (Currently Amended) The process according to ~~any of claim 7, 10, 11, 12 or 13~~ wherein the bodies have a diameter of from 50 nanometers to 500 microns.